Alecensa (alectinib) demonstrated a 22% discount within the danger of demise in contrast with Xalkori (crizotinib) within the frontline setting of sufferers with superior ALK-positive non–small cell lung most cancers (NSCLC), which was discovered to be clinically significant, in response to remaining outcomes of the part 3 ALEX trial introduced in the course of the
Information confirmed that at a median follow-up of 53.5 months with Alecensa and 23.3 months with Xalkori, the median general survival (OS) was 81.1 months in contrast with 54.2 months, respectively. The 7-year OS price was 48.6% with Alecensa versus 38.2% with Xalkori.
“That is most likely one of many longest OS [rates] we’ve ever reported for sufferers with stage 4 non–small cell lung most cancers. Regardless of the numerical distinction, the consequence was not important,” lead examine creator Dr. Tony S. Okay. Mok mentioned in a presentation of the info, explaining that the examine was not powered for OS. “Fifty p.c of sufferers alive at 5 years in a randomized part 3 examine of stage 4 lung most cancers, I feel that is really an achievement.”
The long-term OS enchancment with Alecensa, which was helpful however not important, was noticed throughout most affected person subgroups aside from lively people who smoke and people with an ECOG efficiency standing of two. In these with central nervous system (CNS) metastases, nevertheless, information confirmed that the most important profit was noticed in sufferers who had undergone radiation.
Earlier outcomes of ALEX led to the Meals and Drug Administration approval of Alecensa in April 2024 within the frontline setting for sufferers with superior ALK-positive NSCLC.
Within the open-label, multicenter part 3 ALEX trial, sufferers with superior ALK-positive NSCLC have been randomly assigned to obtain 600 milligrams (mg) of twice-daily Alecensa or 250 mg of twice-daily Xalkori till illness development, unacceptable toxicity, withdrawal from examine, or demise. No crossover was permitted earlier than illness development. Sufferers additionally underwent imaging each eight weeks.
Sufferers should have been 18 years or older, haven’t any prior systemic remedy, and an ECOG efficiency standing of 0 to 2. Stratification elements included ECOG efficiency standing (0 or 1 versus 2), race (Asian versus non-Asian), and baseline CNS metastases (sure versus no).
The first finish level was investigator-assessed progression-free survival (PFS) by way of RECIST 1.1 standards, with secondary finish factors being impartial assessment committee–assessed PFS, time to CNS development, goal response price, length of response, OS and security.
Prior reported information of the ultimate PFS evaluation confirmed an investigator-assessed median PFS of 34.8 months with Alecensa versus 10.9 months with Xalkori. At a median follow-up of 48.2 months, OS information have been immature, and the median OS was not reached with Alecensa versus 57.4 months with Xalkori.
On the ESMO Congress 2025, Mok, who serves because the Li Shu Fan Medical Basis endowed professor and chairman of the Division of Medical Oncology on the Chinese language College of Hong Kong, introduced on the ultimate OS evaluation and long-term security information after a further 6 years of follow-up from the prior OS evaluation. The info cutoff date was April 28, 2025.
Affected person traits have been typically nicely balanced between each arms. CNS metastases by way of an impartial assessment committee have been current in 42.1% of Alecensa-treated sufferers (152 sufferers) versus 38.4% of these on Xalkori (151 sufferers), and 17.1% and 13.9% of sufferers, respectively, obtained prior mind radiation.
Extra information confirmed that the subsequent a number of strains of ALK TKI remedy within the Alecensa (37.5%) and Xalkori arms (47.7%) included lorlatinib (18.4% and 11.9%, respectively), Alunbrig (brigatinib; 10.5% and 10.6%), Xalkori (9.2% and 6.6%), Alecensa (8.6% and 25.2%), Zykadia (6.6% and 19.2%), ensartinib (0.7% and 0%), NVL 655 (0.7% and 0%), and APG 2449 (0 and 0.7%).
Mok famous these OS outcomes usually are not statistically important, doubtlessly because of confounded information from the crossover arm of Xalkori-treated sufferers to Alecensa.
In exploring the OS of sufferers with CNS metastases at baseline, the median OS was 63.4 months in these on Alecensa (59 sufferers) in contrast with 30.9 months for these on the Xalkori arm (53 sufferers), resulting in a 32% discount within the danger of demise. For these with out CNS metastases on Alecensa (93 sufferers) or Xalkori (98 sufferers), the median OS was 94 months versus 69.8 months, respectively.
Moreover, within the group of sufferers who obtained prior mind radiation, the median OS was 92 months with Alecensa (25 sufferers) in contrast with 39.5 months in those that obtained Xalkori (18 sufferers). Those that didn’t have prior mind radiation had a median OS of 46.9 months with Alecensa (34 sufferers) versus 23.7 months on Xalkori (35 sufferers).
Investigator-assessed length of response in responders was a median of 42.3 months with Alecensa (126 sufferers) versus 11.1 months with Xalkori responders (11 sufferers).
Concerning unintended effects, the median length of remedy was 28.1 months with Alecensa and 10.8 months with Xalkori. The commonest unintended effects that led to dose reductions or discontinuations with Alecensa comprised elevated blood bilirubin (5.3% and three.3%, respectively). For Xalkori, this included elevated alanine aminotransferase (8.6% and 6.6%). Grade 3 (extreme) to five (demise) unintended effects have been related between the Alecensa and Xalkori arms (57.9% versus 57.6%, respectively), and severe unintended effects have been 46.1% versus 31.8%; treatment-related unintended effects have been 82.2% versus 89.4%. Unwanted effects with Alecensa that led to demise, remedy discontinuation, dose discount, and dose interruptions occurred in 6.6%, 17.8%, 23%, and 32.2%, respectively. On the Xalkori arm, these charges have been 4.6%, 14.6%, 19.9%, and 28.5%, respectively.
The commonest grade 3 to five unintended effects between each arms included anemia (7.2% with Alecensa versus 0.7% with Xalkori), elevated alanine aspartase (5.3% versus 10.6%), pneumonia (5.3% versus 2%), urinary tract an infection (5.3% versus 0.7%), elevated ALT (4.6% versus 16.6%), elevated blood bilirubin (4.6% versus 0%), elevated blood CPK (3.3% versus 4.6%), and neutropenia (0% versus 6%).
Two p.c of on-study deaths (3 sufferers) of unknown trigger, with no post-mortem carried out, have been suspected to be unrelated to Alecensa.
References
- “Ultimate Total Survival and Security Evaluation of the Section 3 ALEX Research of Alecensa versus Xalkori in Sufferers With Beforehand Untreated, Superior ALK-positive Non-Small Cell Lung Most cancers” by Dr. Tony S. Okay. Mok, et al., Annals of Oncology.
- “Alecensa versus Xalkori in Untreated ALK-positive Non-Small Cell Lung Most cancers” by Dr. Solange Peters, et al., New England Journal of Drugs.
- “FDA Approves Alecensa as First Adjuvant Remedy for Folks With ALK-positive Early-Stage Lung Most cancers,” Genentech information launch, April 18, 2024.
- “Up to date Total Survival and Ultimate Development-Free Survival Information for Sufferers With Remedy-Naive Superior ALK-positive Non-Small Cell Lung Most cancers within the ALEX Research” by Dr. Tony S. Okay. Mok, et al., Annals of Oncology.
For extra information on most cancers updates, analysis and schooling,
